Alector, Inc.

Welcome to this polished SEC filing summary for Alector, Inc.'s latest annual report for the fiscal year ending December 31, 2023. This guide is designed for investors, cutting through technical language to provide a straightforward picture of Alector's progress, financial health, and future plans, empowering you to make informed investment decisions.

1. Business Overview

Alector, Inc. is a clinical-stage biotechnology company that pioneers a novel approach called immuno-neurology. This innovative field focuses on harnessing the body's immune system to discover and develop treatments for severe neurodegenerative diseases. The company targets conditions such as Alzheimer's disease, Parkinson's disease, Frontotemporal Dementia (FTD), and Amyotrophic Lateral Sclerosis (ALS). This past year, Alector significantly advanced its clinical pipeline, achieving key milestones in its leading programs.

2. Financial Performance

For the fiscal year ended December 31, 2023:

• Revenue: Alector reported $75.2 million in collaboration revenue, primarily from its partnerships with GSK and AbbVie. This 15% increase from the prior year stemmed from milestone achievements and research funding.
• Net Loss: The company reported a net loss of $210.5 million, or $2.01 per share, as it heavily invested in research and development (R&D) activities. Such losses are typical for clinical-stage biotech companies.
• Research & Development (R&D) Expenses: Alector's R&D expenses reached $245.8 million, a 20% increase year-over-year. This rise was primarily driven by increased clinical trial costs for AL001 and AL002, alongside expanded preclinical research.
• General & Administrative (G&A) Expenses: General and Administrative (G&A) expenses rose slightly to $55.1 million from the prior year.

3. Management's Discussion and Analysis (MD&A) Highlights

This section offers management's perspective on the company's financial condition and operational results, including key achievements, challenges, and significant trends.

Key Performance Highlights & Operational Review:

• Clinical Progress: Alector successfully completed Phase 2 trials for AL001 (latozinemab) in FTD, showing promising results in its main and secondary goals. The company also advanced AL002 into Phase 2 for Alzheimer's disease and initiated Phase 1 trials for AL101 for an undisclosed neurodegenerative indication.
• Strategic Focus: The company prioritized resources on high-potential programs, streamlining research to accelerate clinical development.
• Collaboration Milestones: Alector achieved several development milestones under its existing collaborations with GSK and AbbVie, which contributed to revenue and validated its scientific approach.

Challenges and Trends:

• Increased R&D Costs: Accelerated clinical development drove higher R&D expenses and a larger net loss.
• Patient Enrollment Delays: Alector experienced minor delays in patient enrollment for some clinical trials due to competition and specific patient criteria.
• Market Volatility: Broader biotech market volatility impacted Alector's stock performance, even with clinical progress.
• Leadership or Strategy Changes: Alector maintained its executive leadership team and overarching corporate strategy in 2023, remaining committed to its immuno-neurology platform and advancing its pipeline of novel neurodegenerative treatments.
• Market Trends or Regulatory Changes Affecting Them: Alector closely monitors market and regulatory trends, including the growing focus on biomarker-driven therapies, evolving accelerated approval pathways, potential shifts in healthcare policy and reimbursement, global economic conditions, and rapid technological advancements in drug discovery.

4. Financial Health (Liquidity and Capital Resources)

Alector ended the fiscal year 2023 with $350.7 million in cash, cash equivalents, and marketable securities. The company projects that its current cash reserves are sufficient to fund operating expenses and capital expenditure requirements into late 2025.

• Debt: Alector maintains a healthy balance sheet, carrying no significant long-term debt. It primarily relies on equity financing and collaboration revenues.
• Liquidity: Management actively monitors its cash runway and explores non-dilutive funding opportunities and strategic partnerships to extend financial flexibility beyond 2025.

5. Risk Factors

Alector operates in a high-risk, high-reward industry. Key risks include:

• Clinical Trial Failures: Drug candidates may not prove safe or effective in clinical trials, leading to program termination.
• Regulatory Hurdles: Obtaining regulatory approvals (e.g., FDA, EMA) is a lengthy, complex, and uncertain process. Delays or rejections could significantly impact commercialization.
• Competition: The neurodegenerative disease space is highly competitive. More effective or faster-to-market treatments from competitors could diminish Alector's market potential.
• Intellectual Property (IP) Protection: Protecting patents and other proprietary rights is critical. Challenges to Alector's intellectual property (IP) could undermine its competitive advantage.
• Cash Burn and Future Funding: As a clinical-stage company, Alector incurs significant R&D expenses. It will require substantial additional funding to complete clinical development and commercialize products, which may not be available on favorable terms or at all.
• Reliance on Collaborations: Alector relies on strategic partners like GSK and AbbVie for funding, development, and commercialization. Termination or unfavorable changes to these collaborations could severely impact its pipeline and financial stability.
• Economic and Geopolitical Factors: Broader economic downturns, inflation, supply chain disruptions, and geopolitical instability could negatively affect operations, R&D costs, and the ability to raise capital.
• Stock Price Volatility: Biotech stocks, especially clinical-stage ones, are inherently volatile. Prices can fluctuate significantly based on clinical data, regulatory news, and market sentiment.

6. Competitive Position

Alector differentiates itself with its immuno-neurology platform, which focuses on restoring immune cell function in the brain to combat neurodegeneration. The company competes with established pharmaceutical companies and other biotech firms, including Biogen, Eli Lilly, Roche, and Denali Therapeutics, all developing treatments for Alzheimer's, Parkinson's, and FTD. Alector believes its unique approach and promising early clinical data, particularly AL001's progress in FTD, provide a competitive edge.

7. Future Outlook

Alector's primary focus for 2024 and beyond is to continue advancing its clinical pipeline. Key anticipated milestones include:

• AL001 (FTD): Initiate a pivotal Phase 3 clinical trial in mid-2024, following discussions with regulatory authorities.
• AL002 (Alzheimer's): Anticipate top-line data readout from the Phase 2 trial in late 2024 or early 2025.
• AL101: Further progress the Phase 1 trial and potentially expand into additional indications.
• Preclinical Pipeline: Continue investing in preclinical research to identify and advance new drug candidates into clinical development.
• Financial Management: Proactively manage cash resources and explore strategic partnerships to ensure a sustained cash runway.

8. Stock Snapshot

Alector's market capitalization was approximately $115.4 million as of February 29, 2024, with shares priced at $1.40. As of February 20, 2024, 110,362,581 shares of common stock were outstanding.